Association between fibrinolysis and leukocyte integrin receptor Mac-1 in leukemia.

白血病中纤溶与白细胞整合素受体 Mac-1 之间的关联。

• 批准号: 12672239
• 负责人: MORISHITA Eriko
• 金额: $ 2.18万
• 依托单位: Kanazawa University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2001
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12672239/
• 关键词: Leukemia; Mac-1; Fibrinolysis; Neutrophilic elastase; Plasminogen; DIC; Acute promyelocytic leukemia; 組織因子; CD14; 凝固亢進; TAT; PIC; 急性白血病; FDP; プラスミン; エラスターゼ

The aim of this study was to assess the expression of Mac-1 (CD11b/CD18 integrin adhension molecules) on the leukemic cells, and to evaluate the plasmin activity in leukemic cell homoginates and the concentration of elastase-α 1-proteinaseinhibitor (E-α IPI) complex. A total of 14 patients were examined : 11 with acute leukemia (AML 7, ALL 3, LGL leukemia 1) ; 1 with myelodysplasia syndrome (RAEB-T) ; 2 with chronic myelocytic leukemia (CML).Mac-1 on leukemic cell was detected by flow cytometory, whereas plasmin activity was measured using chromogenic assay by S2251, and concentrations of E-α IPI complex were assayed using a sandwich-type immunoassay.Mac-1 expression was found to be higher in the patients with acute myelomonocytic leukemia (AMMoL) than other leukemic patients, especially acute promyelocytic leukemia (APL). On the other hand, plasmin activation markedly increased in APL patients with DIC. Marked to moderate elevation of E-E_0 IPI complex levels was observed in patients with APL, AMMoL or CML. The concentrations of E- a IPI complex did not show any significant differences between patients with DIC and patients without DIC.From these results, it is suggested that hyperfibrinolysis in leukemia, especially APL, participates in leukocyte elastase rather than Mac-1.

本研究的目的是评估白血病细胞上Mac-1（CD11b/CD18整合素粘附分子）的表达，并评估白血病细胞匀浆中纤溶酶的活性和弹性蛋白酶-α1-蛋白酶抑制剂（E- α IPI) 复合物总共检查了 14 名患者：11 名患有急性白血病（AML 7 名、ALL 3 名、LGL 白血病 1 名）。 ; 1 患有骨髓增生异常综合征 (RAEB-T); 2 患有慢性粒细胞白血病 (CML)。通过流式细胞术检测白血病细胞上的 Mac-1，而通过 S2251 显色测定来测量纤溶酶活性，以及​​ E-α IPI 浓度使用夹心型免疫分析法对复合物进行检测。发现急性髓单核细胞白血病 (AMMoL) 患者中 Mac-1 表达较高与其他白血病患者相比，尤其是急性早幼粒细胞白血病 (APL)，APL、AMMoL 或 CML 患者的纤溶酶显着升高。 E-a IPI复合物的浓度在DIC患者和非DIC患者之间没有显示出任何显着差异。从这些结果表明，白血病中纤溶亢进，尤其是APL 参与白细胞弹性蛋白酶而不是 Mac-1。

项目成果

Morishira E., et al.: "Atorvastatin reduces plasma lelvels of factor Vll activity and factor Vll antigen in patients with hyperlipidemia"Journal of Atherosclerosis and Thrombosis. (in press).

Morishira E.等人：“阿托伐他汀降低高脂血症患者的凝血因子VII活性和凝血因子VII抗原的血浆水平”动脉粥样硬化和血栓形成杂志。

青島敬二, 森下英理子 他: "血液透析患者における血中Tissue factor pathway inhibitor (RFPI)の1年間の変動とヘパリン負荷テストによるTFPIの変化"腎臓. 22. 224-227 (2000)

Keiji Aoshima、Eriko Morishita 等人：“血液透析患者肝素负荷试验导致的血液组织因子途径抑制剂 (RFPI) 的一年波动和 TFPI 变化”Kidney。

山崎雅英: "抗リン脂質抗体症候群の病態について"日本血栓止血学会誌. 12. 333 (2001)

Masahide Yamazaki：“关于抗磷脂抗体综合征的病理学”日本血栓和止血学会杂志 12. 333 (2001)。

Asakura H., Morishira E., et al.: "An enhanced fibrinolysis parevents the development of multiple organ failure in desseminated intravascular coagulation in spite of much activation of blood coagulation"Critical Care medicine. 29. 1164-1168 (2001)

Asakura H.、Morishira E.等人：“尽管血液凝固有大量激活，但纤维蛋白溶解的增强可避免弥散性血管内凝血中多器官衰竭的发生”，重症监护医学。

Asakura H, Morishita E, et al: "All-trans retinoic acid is partially effective against lipopolysaccharide-induced but not against tissue-factor-induced DIC in rat models."Blood Coagulation and Fibrinolysis. 12. 301-306 (2001)

Asakura H、Morishita E 等人：“在大鼠模型中，全反式视黄酸对脂多糖诱导的 DIC 部分有效，但对组织因子诱导的 DIC 无效。” 凝血和纤维蛋白溶解。